City University

GERMAGIC(TM) PET Hosts "Social Inclusion Charity Run with Pets"

Retrieved on: 
Monday, March 18, 2024
Yee, Health, New Territories, Social, Certification, Social exclusion, Pet, Environment, Companion, City University, Business, PET, Life, SGS, Bacteria, Virus, APEL, Athlete, Human, Dog, Biochemistry, Love, QPP, Safety, Metro Broadcast Corporation, Cat, Creative industries

GERMAGIC(TM) PET is the title sponsor of the "Social Inclusion Charity Run with Pets" on 17 March.

Key Points: 
  • GERMAGIC(TM) PET is the title sponsor of the "Social Inclusion Charity Run with Pets" on 17 March.
  • To provide pets with more care and protection, GERMAGIC(TM) PET continuously innovates and utilizes its scientific research technology to develop various green pet health products, thus promoting social inclusion and sustainable development.
  • GERMAGIC(TM) PET products utilize GERMAGIC(TM)'s encapsulation technology and molecular materials to comprehensively support and protect pet health.
  • This certification not only recognizes the quality of GERMAGIC(TM) PET products but also sets higher quality standards for the pet health industry.

CASSAVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Cassava Sciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, April 5, 2024
Cassava Sciences, Science, Initiative, Alzheimer's disease, Telephone, Patient, Defendant, City University, Journal, Biomarker, News, Scientific misconduct, Complaint, P.C, Neurobiology of Aging, Cognition, Safety, Data management, FDA, Pharmaceutical industry

Our investigation concerns whether the board of directors of Cassava have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Cassava have breached their fiduciary duties to the company.
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • However, in response, Cassava denied the allegations in the Citizen Petition and instead touted the effectiveness of simufilam and the efficacy of the Company's research programs.
  • On this news, Cassava's stock price fell $2.68 per share, or 15.28%, to close at $14.86 per share on October 13, 2023.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – SAVA

Retrieved on: 
Sunday, March 31, 2024
Cassava Sciences, Prior, Initiative, Science, District court, Patient, City University, Journal, Biomarker, News, Ext, LLP, Cassava, Complaint, Person, Neurobiology of Aging, Cognition, Safety, Pomerantz, Action Replay, Data management, FDA, Court, Pharmaceutical industry

NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA).

Key Points: 
  • NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA).
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SIAM Announces Class of 2024 Fellows

Retrieved on: 
Thursday, March 28, 2024
CNRS, Editorial, Mathematics, Sorbonne University, Climate change, Algorithm, Masaryk University, Utrecht University, Data science, State university system, Cornell University, Systems theory, University of Utah, City University, University of Massachusetts, Research, University of British Columbia, Platelet, University, Software, IBM, University of Cambridge, University of Exeter, Statistics, Industrial, Rutgers University, University of Zurich, University of Waterloo, Stanford University, Virginia Tech, Probability, Lehigh University, Engineering, Lawrence Berkeley National Laboratory, Information technology

Philadelphia, PA, March 28, 2024 (GLOBE NEWSWIRE) -- Society for Industrial and Applied Mathematics (SIAM) is pleased to announce the 2024 Class of SIAM Fellows.

Key Points: 
  • Philadelphia, PA, March 28, 2024 (GLOBE NEWSWIRE) -- Society for Industrial and Applied Mathematics (SIAM) is pleased to announce the 2024 Class of SIAM Fellows.
  • Through their various contributions, SIAM Fellows form a crucial group of individuals helping to advance the fields of applied mathematics, computational science, and data science.
  • Hans De Sterck, University of Waterloo, is being recognized for contributions to scientific computing methods including multilevel and nonlinear solvers, and for exemplary scientific leadership and service to SIAM.
  • Fred S. Roberts, Rutgers University, is being recognized for distinguished research in discrete mathematics, leadership of major research centers, and service to SIAM.

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Retrieved on: 
Thursday, March 28, 2024
Cassava Sciences, Science, Initiative, Alzheimer's disease, Patient, City University, Journal, Biomarker, News, LLP, Scientific misconduct, Neurobiology of Aging, Cognition, Safety, Advertising, Data management, FDA, Court, Pharmaceutical industry

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Cassava’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ).

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, NYCB, Amylyx, and InMode and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, March 26, 2024
Apoptosis, Patient, AMX0035, Science, New York Community Bank, NYCB, P.C, Initiative, ACL, Scientific misconduct, IBD, Confidentiality, Safety, Injury, Data management, Food, Signature, Cassava Sciences, ALS, Alzheimer's disease, Defendant, Food and Drug Administration, Journal, Amyotrophy, News, Prescription, Amylyx Pharmaceuticals, Dentist, FDA, City University, Biomarker, Dermatology, Complaint, Investor's Business Daily, Neurobiology of Aging, Cognition, Assumption, Category, BBC World Service, Evercore, Cassava, Pharmaceutical industry

The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.

Key Points: 
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • However, in response, Cassava denied the allegations in the Citizen Petition and instead touted the effectiveness of simufilam and the efficacy of the Company's research programs.
  • On this news, Cassava's stock price fell $2.68 per share, or 15.28%, to close at $14.86 per share on October 13, 2023.
  • For more information on the InMode class action go to: https://bespc.com/cases/INMD

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – SAVA

Retrieved on: 
Saturday, March 23, 2024
Cassava Sciences, Prior, Initiative, Science, District court, Patient, City University, Journal, Biomarker, News, Ext, LLP, Cassava, Complaint, Person, Neurobiology of Aging, Cognition, Safety, Pomerantz, Action Replay, Data management, FDA, Court, Pharmaceutical industry

NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA).

Key Points: 
  • NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA).
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, NYCB, Amylyx, and InMode and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, March 22, 2024
Apoptosis, Patient, AMX0035, Science, New York Community Bank, NYCB, P.C, Initiative, ACL, Scientific misconduct, IBD, Confidentiality, Safety, Injury, Data management, Food, Signature, Cassava Sciences, ALS, Alzheimer's disease, Defendant, Food and Drug Administration, Journal, Amyotrophy, News, Prescription, Amylyx Pharmaceuticals, Dentist, FDA, City University, Biomarker, Dermatology, Complaint, Investor's Business Daily, Neurobiology of Aging, Cognition, Assumption, Category, BBC World Service, Evercore, Cassava, Pharmaceutical industry

The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.

Key Points: 
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • However, in response, Cassava denied the allegations in the Citizen Petition and instead touted the effectiveness of simufilam and the efficacy of the Company's research programs.
  • On this news, Cassava's stock price fell $2.68 per share, or 15.28%, to close at $14.86 per share on October 13, 2023.
  • For more information on the InMode class action go to: https://bespc.com/cases/INMD

Saint Peter’s Leads as First NJ Health System with Upfront Tuition Coverage for Employees

Retrieved on: 
Tuesday, March 19, 2024
Education, Arizona State University, Learning, Caregiver, Partnership, City University, Policy, University, CUNY, LOS, LEAP, Saint, Nursing

The Learning, Education and Advancement Program (LEAP) , available to Saint Peter’s full- and part-time employees, makes educational growth accessible so employees can earn valuable credentials and degrees to advance their professional careers in health care.

Key Points: 
  • The Learning, Education and Advancement Program (LEAP) , available to Saint Peter’s full- and part-time employees, makes educational growth accessible so employees can earn valuable credentials and degrees to advance their professional careers in health care.
  • The initiative complements Saint Peter’s existing tuition reimbursement policy, improving access to learning by lowering the financial barrier of upfront tuition costs for employees.
  • “As a mission-based healthcare system, this program underscores Saint Peter’s commitment to transforming careers and our community,” said Laura Atkinson, vice president and chief human resources officer at Saint Peter’s Healthcare System.
  • "Saint Peter’s shares our dedication to advancing employees’ careers through equitable access to education," said Craig Maloney, CEO of InStride.

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Retrieved on: 
Tuesday, March 19, 2024
Cassava Sciences, Science, Initiative, Alzheimer's disease, Patient, City University, Journal, Biomarker, News, LLP, Scientific misconduct, Neurobiology of Aging, Cognition, Safety, Advertising, Data management, FDA, Court, Pharmaceutical industry

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Cassava’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).